- Researchers at IRB Barcelona discover unexpected patterns in mutation risks across individuals, uncovering 13 distinct genomic patterns.
- The study provides crucial insights into cancer evolution, identifying the genes most affected by changes in mutation risk and shedding light on the dynamic relationship between cell proliferation, mutations, and epigenetic alterations.
- The work has been published in the journal Nature Cancer.
Mutations, which occur continuously in every cell of our bodies, are a key contributor to cancer, ageing, and neurodegeneration. While exposure to mutagenic chemicals, or mistakes in cellular processes during DNA replication contribute to these mutations, the exact distribution and patterns of these changes across human chromosomes have remained a mystery until now.
Dr. Fran Supek, ICREA researcher and head of the Genome Data Science lab at IRB Barcelona, and Marina Salvadores, PhD student in the same laboratory, have delved into the landscape of DNA mutations, unveiling unexpected patterns that differentiate individuals in terms of mutation risk.
Previous work by the laboratory identified a "genomic spellchecker," a DNA repair mechanism devoted to reducing mutation risks in key parts of human chromosomes. Building upon these findings, the current study aimed to determine whether mutation risk varies between individuals and, if so, to identify the mechanisms driving these differences.
“This research not only expands our understanding of the factors influencing mutation rate distribution but it also has significant implications for cancer evolution, therapeutic strategies, and advancements in regenerative medicine,” explains Dr. Supek.
A genomic ‘big data’ analysis
To address these questions, the researchers conducted a comprehensive analysis of genome sequences from over 4,000 tumours from various organs. Unlike previous studies focusing on tissue-specific mutation risks, this study specifically targeted individual differences in susceptibility to mutations.
Employing a genomic "big data" approach, the team used machine learning algorithms to identify recurrent patterns across chromosome segments. They discovered 13 distinct patterns, with 10 corresponding to different types of tissue. Unexpectedly, the remaining three patterns were observed in almost all the tissues, thereby revealing that the density of mutations in specific genes varies significantly between individuals.
Connecting the dots
To understand these unexpected patterns, the researchers examined additional data, including gene expression and genetic aberrations, in cancer cells. The analysis uncovered a surprising correlation between increased cell proliferation and alterations in mutation risks. Disruptions in two crucial tumour-suppressor genes, TP53 and RB1, known to regulate the cell division cycle, were identified as key influencers, causing changes in the risk of mutations across chromosomes.
These chromosome segments not only presented altered mutation risks but also large-scale "remodelling" of usually inactive chromosomal regions. “This remodelling, which is correlated with increased cell proliferation, mirrored the changes in mutation risks, providing unique insight into the interplay between mutations and epigenetic alterations,” explains Marina Salvadores, first author of the study.
Decoding cancer evolution
The implications of this study extend beyond fundamental research. By identifying the cancer-causing genes most affected by changes in mutation risk between individuals, the scientists have provided a roadmap for anticipating the trajectory of cancer evolution. This knowledge is especially relevant for anticipating responses to cancer treatment, as it can help to predict the development of drug-resistance mutations in tumours.
The study also offers valuable insights into the epigenetics of human cells, highlighting that the epigenome undergoes dramatic changes in response to increased or disrupted cell proliferation. This understanding has potential implications for cell reprogramming and regenerative medicine, opening up new avenues for future research and therapeutic interventions.
This study has received funding from the ERC and the Spanish Ministerio de Ciencia e Innovación.
Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers
Marina Salvadores & Fran Supek
Nature Cancer (2024) DOI: 10.1038/s43018-023-00707-8
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).